BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) + BCG( 50mg/Instillation)
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-muscle Invasive Bladder Cancer
Conditions
Non-muscle Invasive Bladder Cancer
Trial Timeline
Jul 21, 2014 → Dec 1, 2038
NCT ID
NCT02138734About BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) + BCG( 50mg/Instillation)
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) + BCG( 50mg/Instillation) is a phase 1/2 stage product being developed by ImmunityBio for Non-muscle Invasive Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02138734. Target conditions include Non-muscle Invasive Bladder Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02138734 | Phase 1/2 | Recruiting |
Competing Products
18 competing products in Non-muscle Invasive Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Durvalumab + BCG | AstraZeneca | Phase 3 | 77 |
| Durvalumab + Monalizumab | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + BCG | Merck | Phase 3 | 77 |
| Pembrolizumab | Merck | Phase 1/2 | 41 |
| Sacituzumab tirumotecan + Rescue medication + Supportive care measures | Merck | Phase 1/2 | 41 |
| Eciskafusp Alfa + BCG Medac Strain | Roche | Phase 1 | 33 |
| PF-06801591 + Bacillus Calmette-Guerin | Pfizer | Phase 3 | 76 |
| PF-08052667 + Sasanlimab + BCG + PF-02921367 | Pfizer | Phase 1 | 32 |
| N-803 and BCG + N-803 and Gemcitabine | ImmunityBio | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Pre-clinical | 20 |
| UGN-301 + UGN-201 + Gemcitabine | UroGen Pharma | Phase 1 | 28 |
| AU-011 | Aura Biosciences | Phase 1 | 25 |
| TARA-002 | Protara Therapeutics | Phase 1 | 25 |
| TARA-002 | Protara Therapeutics | Phase 2 | 44 |
| TARA-002 | Protara Therapeutics | Phase 1 | 25 |
| PD-L1/IDO Peptide Vaccine + Pembrolizumab | IO Biotech | Phase 1 | 25 |
Other Products from ImmunityBio
NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxelPhase 3
74
N-803 + Tislelizumab + DocetaxelPhase 3
74
Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)Phase 3
74
N-803 and BCG + N-803Phase 2/3
62
hAd5-S-Fusion+N-ETSD + Placebo (0.9% (w/v) saline)Phase 2/3
62